Post-marketing evaluation of Aprepitant: multicenter, non-randomized, controlled, open-label registration study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-17010567

Enrollment

Unknown

Registered

2017-02-07

Start date

2017-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

standard therapy group:DXM+5-HT3 inhibitor+Aprepitant

non-standard therapy group:DXM+5-HT3 inhibitor

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male or female, over 18 years old, cytological and histological diagnosis of malignant tumor. 2. Study group: patients prescriped aprepitant in hospital. 3. Control group: patients initially treated with cisplatin and standard prevent anti-nausea scheme. 4. Willing to participate in research and sign a consent form. 5. to be able to read, understand and complete the patient questionnaire.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
remission rate;	—

Secondary

Measure	Time frame
vomiting;Nausea;	—

Countries

China

Contacts

Public ContactXiao-yang Lu

The First Hospital, College of Medicine, Zhejiang University

lxy00711@126.com+86 13605715886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026